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Among the 518 protein kinases encoded by the human kinome, several of them act as oncoproteins in human cancers. Like other
eukaryoticgenes,oncogenesencodingproteinkinasesarefrequentlysubjectedtoalternativesplicingincodingaswellasnoncoding
sequences. Inthe presentpaper, we will illustratehow alternative splicing can signiﬁcantly impact onthe physiological functions of
oncogenicproteinkinases,asdemonstratedbymousegeneticmodelstudies.Thisincludesexamplesofmembrane-boundtyrosine
kinases receptors (FGFR2, Ret, TrkB, ErbB4, and VEGFR) as well as cytosolic protein kinases (B-Raf). We will further discuss
how regular alternative splicing events of these kinases are in some instances implicated in oncogenic processes during tumor
progression (FGFR, TrkB, ErbB2, Abl, and AuroraA). Finally, we will present typical examples of aberrant splicing responsible for
the deregulation of oncogenic kinases activity in cancers (AuroraB, Jak2, Kit, Met, and Ron).
1.Introduction
The process of alternative splicing increases the complexity
of the proteome encoded by higher eukaryotic genomes
through the synthesis of diﬀerent products from a single
gene. Genes encoding for protein kinases do not escape this
rule. While the whole human genome sequencing revealed
518proteinkinasesencodinggenes[1],arecentbioinformat-
ics survey identiﬁed a larger repertoire of about 918 putative
protein kinases represented mainly by splice variants from
these 518 human genes [2]. This retrospectively gives credit
to Tony Hunter’s previous witty estimate of “A thousand
and one protein kinases” [3]. Protein kinases are among
the largest families of genes in eukaryotes, representing
approximately 1.7% of all human genes [1]. They are
implicated in most of the essential cellular functions, and
their deregulation often leads to pathological disorders,
including cancer. Alteration of the expression and/or the
activity of a number of protein kinases by point mutations,
chromosomal translocations, or epigenetic mechanisms can
directly initiate or contribute to the development of tumors.
The ﬁrst example came from the seminal discovery of the
existence of cellular oncogenes, when the tyrosine kinase c-
Src was identiﬁed thanks to its retroviral counterpart in the
Rous Sarcoma Virus [4]. Since then, numerous oncogenic
protein kinases have been discovered, among which EGFR,
Abl, Kit, and B-Raf represent typical examples of success
in the development of targeted drug therapy [5–7]. While
in most cases constitutive activation of the protein catalytic
activity is achieved by mutation or overexpression, aberrant
splicing has been sometimes incriminated in the deregula-
tion of oncogenic kinases in cancer. In addition, although
numerous publications have reported the modulation of
kinase activity of oncogenic kinases through alternative
splicing, most of these studies have been conducted only in
vitro. The physiological consequences of alternative splicing
in genes encoding oncogenic kinases were not frequently
investigated in nonpathological conditions. In the present
review we will provide examples of in vivo studies exploiting
mouse models that clearly disclosed speciﬁc physiological
functionsfornaturallyoccurringsplicevariantsofoncogenic2 Journal of Nucleic Acids
Table 1: Regulatory mechanisms of oncogenic kinases activity by alternative splicing.
Kinase name Kinase type Splicing Regulation type
Fyn Cytosolic
tyrosine kinase
Alternative use of
exon 7a or 7b
upstream of the
kinase domain
Kinase activity
modulation by
interfering with
autoinhibition
Fak Focal adhesion
tyrosine kinase
Multiple alternative
splicing upstream of
the kinase domain
Kinase activity
modulation by
interfering with
autophosphorylation
B-Raf
Cytosolic
serine/threonine
kinase
Alternatively spliced
exon 8b and 9b
upstream of the
kinase domain
Kinase activity
modulation by
interfering with
phosphorylation and
autoinhibition
Intact
kinase
domain
Ret
Membrane-
bound tyrosine
kinase receptor
C-terminal alternative
splicing generating
three isoforms
Modulation of
signaling partners
binding
ErbB4
Membrane-
bound tyrosine
kinase receptor
N- and C-terminal
alternative splicing
generating four
isoforms
Modulation of
partners binding,
cleavage, and
subcellular
localization
FGFR1
FGFR2
FGFR3
Membrane-
bound tyrosine
kinase receptors
Alternative use of
exon 8 or 9 generating
distinct extracellular
immunoglobulin-like
domain III
Modiﬁed FGF
binding speciﬁcity
A-Raf
Cytosolic
serine/threonine
kinase
Intronic sequences
retention introducing
stop codons
Dominant negative
Kinase
domain
truncation
TrkB
TrkC
Membrane-
bound tyrosine
kinase receptors
C-terminal alternative
splicing replacing
kinase domain by
short amino acid
sequences
Ligand sequestering,
dominant negative
and/or speciﬁc
signaling functions
VEGFR1
VEGFR2
Membrane-
bound tyrosine
kinase receptors
C-terminal alternative
splicing eliminating
the kinase and
transmembrane
domains
Synthesis of
secreted/soluble
extracellular
ligand-binding
domains
protein kinases. We will also discuss some examples of
oncogenic kinases whose normal or aberrant splice variants
are associated with a potential role in tumor progression.
2. Mechanisms of Oncogenic Kinase Functional
Regulation through AlternativeSplicing
Alternative splicing allows a single primary transcript to
be spliced in several distinct mature mRNAs leading to
expression of protein isoforms with diﬀerent structural
and functional properties [8]. One can distinguish two
main categories of mechanisms by which alternative splicing
can functionally regulate oncogenic protein kinases. The
ﬁrst class includes alternative splicing which maintains the
catalytic activity whereas the second class consists of protein
products that have lost a functional kinase domain (Table 1).
In the ﬁrst category, the incorporation of alternatively
spliced sequences within the open reading frame keeps intact
thekinasedomain.Inmostcasesforwhichfunctionalstudies
have been conducted, such a mechanism allows a ﬁne-tuned
regulation of the kinase activity depending on the presence
or absence of these additional amino acid sequences. At
the molecular level, the incorporated sequences can impact
on the catalytic activity by several distinct mechanisms.
Posttranslational modiﬁcations such as phosphorylation
are frequently used to regulate protein kinases activity.
For example, autophosphorylation on Tyr-397 of FAK, a
nonreceptor tyrosine kinase that acts as a primary regulator
of focal adhesion signaling to regulate cell proliferation,
survival, and migration, is a critical event, allowing binding
of Src family kinases and activation of downstream signaling
pathways. Molecular studies have shown that tissue-speciﬁcJournal of Nucleic Acids 3
alternative splicing can dramatically alter the mechanism
of autophosphorylation of FAK, thereby modifying its
oncogenicactivity[9].Likewise,B-Rafisoformsgeneratedby
alternative splicing are diﬀerentially regulated by phospho-
rylation mechanisms in a complex manner [10, 11]. B-Raf
is a member of the Raf family of cytosolic serine/threonine
kinases, which act as Ras eﬀectors and MEK kinases in
the canonical RAS/RAF/MEK/ERK signaling pathway [12].
Phosphorylation on both Ser-365 and Ser-429 participates in
the diﬀerential regulation of B-Raf isoforms through distinct
mechanisms (Figure 1). Alternatively spliced exon 8b favors
Ser-365 phosphorylation, leading to inhibition of the kinase
activity whereas B-Raf isoforms containing alternatively
spliced exon 9b are less eﬃciently phosphorylated on this
residue,inagreementwiththeirelevatedactivity.Incontrast,
Ser-429 is equally phosphorylated in all B-Raf isoforms, but
its phosphorylation diﬀerentially regulates the activity of B-
Raf, resulting in activation or inhibition of 9b- and 8b-
containing isoforms, respectively [11].
In several instances, incorporation of additional sequen-
ces within the protein imposes novel structural constraints,
which can modify intramolecular interactions. Thus, alter-
native splicing in the linker region of both B-Raf and
Fyn, a member of Src family tyrosine kinases, modulates
the autoinhibition imposed by the N-terminus regulatory
domain on the C-terminus catalytic domain [11, 13].
Another mechanism by which alternative splicing can
interfere with the biochemical and biological activity of
oncogenic kinases is the change in the repertoire of their
partners. This can either be dependent or independent on
phosphorylation and the structural constraints mentioned
above. A typical example is provided by the gene encoding
the tyrosine kinase receptor Ret. Diﬀerential splicing of
Ret transcripts results in the generation of three isoforms,
Ret9, Ret43, and Ret51, whose C-terminal amino acid
tails diﬀer after Tyr-1062, and which display diﬀerential
oncogenic activities (Figure 1)[ 14]. Amino acid changes in
the sequences surrounding Tyr-1062 residue are responsible
for the diﬀerential binding on phosphorylated Tyr-1062 of
several key signaling molecules such as Shc, Grb2, and the
ubiquitin ligase Cbl [15–17].
The geneencoding ErbB4, another tyrosine kinase recep-
tor, also undergoes complex alternative splicing producing
both juxtamembrane (JM-a and JM-b) and cytoplasmic
(CYT-1 and CYT-2) isoforms (Figure 1). The 16-amino acid
CYT-1 speciﬁc sequence, which is absent from CYT-2 iso-
forms, contains a binding site for the p85 regulatory subunit
of PI3K [18]. In addition, it mediates ErbB4 ubiquitination
and endocytosis by providing a binding site for the WW
domain-containing HECT-type E3 ubiquitin ligase Itch.
Consequently, CYT-1 isoforms are eﬃciently endocytosed
whereas CYT-2 isoforms are impaired in endocytosis [19].
The JM-a isoforms contain a metalloprotease cleavable
extracellular domain whereas JM-b isoforms are resistant to
cleavage [20]. The ligand-dependent proteolysis of ErbB4
JM-a isoforms releases soluble intracellular domains of
80kDa, s80Cyt2, and s80Cyt1, which exhibit nuclear cyto-
plasmic shuttling and diﬀer by the above mentioned 16
amino acid CYT-1 speciﬁc sequence absent from CYT-2
isoforms [18, 19].
The ﬁbroblast growth factor (FGF) receptor (FGFR)
family of tyrosine kinases provides another remarkable
example of how alternative splicing can be used to vary the
repertoire of functional interactions with profound physio-
logical consequences. The FGF family of ligands comprises
22 members, and FGFR signaling activity is regulated by
the binding speciﬁcity of ligands and receptors [21]. This
speciﬁcity largely relies on the immunoglobulin-like loop III
of the extracellular ligand-binding domain of FGFRs [21].
Three of the four FGFRs, FGFR1, 2, and 3, express splice
variants, which alternatively use exon 8 or 9 to encode the
C-terminal half of this immunoglobulin-like domain III,
generating IIIb and IIIc receptor isoforms with diﬀerent
aﬃnities for FGFs (Figure 1)[ 22]. For instance, FGFR2-
IIIb binds FGF7 and FGF10, but not FGF2 whereas the
FGFR2-IIIc isoform binds FGF2 and FGF18, but not FGF7
and FGF10 [21]. This provides each isoform a speciﬁc
physiological function during development, which is further
described in the next section.
Thesecondmainclassofoncogenickinasesplicevariants
is composed of truncated proteins devoid of the catalytic
kinase domain (Table 1). Such alternative splicing often
results in the synthesis of a polypeptide endowed with
dominant negative properties. However, this does not appear
to be always the case and putative speciﬁc and kinase-
independent functions have been proposed for such splice
variants. A well-characterized dominant negative function
was reported in the case of A-Raf, a cytosolic kinase closely
related to B-Raf [12] .T h eA - R a fg e n eu n d e r g o e sa l t e r n a t i v e
splicing, which generates truncated isoforms containing the
Ras-binding domain but lacking the kinase domain. These
splicing isoforms, whose expression is tightly regulated by
extraandintracellularcues,preventERKsignalingactivation
by titrating the upstream activators Ras GTPases [23, 24].
However the physiological relevance of these observations
await in vivo evidence.
The generation of truncated isoforms lacking a kinase
domain is frequently observed within the family of mem-
brane-bound tyrosine kinase receptors. Trk receptors are
a family of three tyrosine kinases (TrkA, TrkB, and TrkC)
activated by neuropeptides of the neurotrophin family,
thereby regulating cell survival, proliferation, and the fate of
neural precursors [25]. In addition to their roles in the adult
nervous system, where they regulate synaptic strength and
plasticity, Trk receptor deregulation has been also implicated
in human cancers. Complex alternative splicing results in the
expression of diﬀerent truncated TrkB and TrkC receptors
lacking the kinase domain, whose functions are not com-
pletely understood [25, 26]. Despite some evidence suggest-
ing that truncated receptors can trigger intracellular signal-
ing alone, tyrosine kinase activity appears to be necessary for
most Trk receptor-mediated responses to neurotrophins. It
has been proposed that the truncated receptors can raise the
local eﬀective neurotrophin concentration by sequestering
and/or presenting neurotrophins to neurons expressing full-
length Trk receptors. However, when expressed on the same
neuron as a full-length Trk receptor, truncated receptors4 Journal of Nucleic Acids
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Figure 1:Splicevariantsofoncogenickinasesstudiedinmousemodels.Thevariousstructuraldomainsofoncogenickinasesarerepresented
by cylinders. Amino acid sequences encoded by alternatively spliced exons are represented in pink, green, and blue. Abbreviations:
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inhibit ligand-induced activation of Trk kinase activity
by forming nonproductive heterodimers, thereby acting as
dominant negative proteins [25]. For example, the human
TrkB gene encodes C-terminal truncated receptors; TrkB-T1
and TrkB-T2, which are generated by the alternative usage of
exon16orexon19,respectively,containingtranslationalstop
codons(Figure 1)[25,26].TrkBisthefunctionalreceptorfor
brain-derived neurotrophic factor (BDNF) and both TrkB-
T1 and TrkB-T2 have the ability to bind it. Although they
can act as dominant negative inhibitors of the full-length
receptor by preventing ligand-induced phosphorylation, it
has been suggested that the truncated isoforms may have
signaling properties distinct from those of the full-length
TrkB, such as evoking calcium signaling and mediating Rho
GDP dissociation inhibitor 1 function [27–29].
Another example of kinase domain truncation by alter-
native splicing is provided by the VEGFR (vascular endothe-
lial growth factor (VEGF) Receptor) family, which encodes
membrane-bound tyrosine kinase receptors for VEGFs act-
ing as key regulators of vasculogenesis, angiogenesis, and
lymphangiogenesis, both in physiological conditions and in
cancer [30, 31]. VEGF-A binds to both VEGF receptor 1
(VEGFR-1, also named Flt-1) and VEGFR-2 (also named
KDR), thereby regulating vasculogenesis and angiogenesis
respectively whereas VEGF-B binds only to VEGFR-1 regu-
lating vasculogenesis. On the other hand, VEGFR-2 is also
involved in lymphangiogenesis through activation by VEGF-
C and VEGF-D. VEGFR-1 and VEGFR-2 undergo alternative
splicing of their cytoplasmic C-terminal domain resulting in
truncated receptors (Figure 1)[ 32–34]. However, unlike the
Trk family members, both the kinase and transmembrane
hydrophobic domains are eliminated, thereby generating
secreted soluble extracellular domains that have retained
their ligand-binding capacity and act as ligand traps.
The following section will review in depth examples of
the physiological consequences of the various mechanisms
described above. In addition, other mechanisms of regula-
tion by alternative splicing were reported in very speciﬁc
cases of tumor-associated splice variants of protein kinases.
These will be discussed in the last section.
3. Physiological Functionsof Oncogenic
KinaseSpliceVariantsRevealed by
GeneticallyEngineeredMouseModels
As described above, alternative splicing can be used either
to allow subtle regulation of protein kinase activity or to
provide additional or dominant negative functions to these
proteins, suggesting that the impact of alternative splicing on
physiological processes can strongly vary depending on the
mechanism. Although alternative splicing has been reported
in a vast number of oncogenic kinases encoding genes,
experimental evidence for a physiological role is lacking for
most of the cases. In this section we will describe typical
examples of speciﬁc functions attributed to splicing variants
of oncogenic kinases revealed by genetically engineered
mouse models. These in vivo studies have highlighted the
physiological importance of alternative splicing in both
fundamental processes during development and more spe-
cialized functions such as behavior.
3.1. FGFR2. As mentioned above, alternative splicing in the
extracellular domain of FGFRs results in diﬀerential binding
of various FGFs. In general, the IIIb and IIIc isoforms of
FGFRs are often expressed on epithelial and mesenchymal
cells, respectively, while their speciﬁc ligands show an
opposite pattern of expression, allowing signaling to occur in
aparacrinefashionbetweenadjacenttissues[21,22].Among
FGFRs, alternative splicing of FGFR2 receptor has been the
best studied in animal models (Figure 1). FGFR2-IIIb is
expressed in the surface ectoderm and in the endothelium of
internal organs throughout development, while FGFR2-IIIc
isexpressedintheparaxialandlateralmesoderm,inthelimb
bud and branchial arch mesenchyme and later in muscle and
other mesenchymal tissues, including the periphery of bone
forming cartilage models [35, 36]. The speciﬁc functions of
both FGFR2-IIIb and FGFR2-IIIc isoforms were investigated
in mouse models using diﬀerent strategies. With regard to
FGFR2-IIIb, two diﬀerent mouse lines deﬁcient for FGFR2-
IIIb were generated, either by classical exon 8 ablation or
by introducing a stop codon and an IRES-LacZ transgene
in exon 8 [35, 37]. Noteworthily, the expression of FGFR2-
IIIc, the other alternatively spliced isoform, was not aﬀected,
a n db o t hm o d e l sr e s u l t e di ns i m i l a rp h e n o t y p e s .T h el o s so f
FGFR2-IIIb abrogates limb outgrowth with multiple defects
in branching morphogenesis, a phenotype similar to that of
the loss of function mutation of FGF10, which binds FGFR2-
IIIbbutnotFGFR2-IIIc.Althoughviableuntilbirth,FGFR2-
IIIb null mice display severe defects of the limbs, lung, and
anterior pituitary gland [35, 37]. The development of these
structures appears to initiate, but then fails with the tissues
undergoing extensive apoptosis. FGFR2-IIIb null mice also
show developmental abnormalities of the salivary glands,
inner ear, teeth, and skin, as well as minor defects in skull
formation [35].
The speciﬁc functions of the other receptor isoform,
FGFR2-IIIc, were also investigated using either a knock-
out approach eliminating exon 9 or a knockin strategy
introducing a stop codon in exon 9 [36, 38]. In contrast
with FGFR2-IIIb studies, the results from both strategies
used for FGFR2-IIIc were not fully concordant. Knockin-
mediated loss of FGFR2-IIIc expression resulted in a reces-
sive viable phenotype with craniosynostosis and retarded
development of the axial and appendicular skeleton, causing
dwarﬁsm and misshapen skull [36]. In exon 9 knockout
mice, however, heterozygotic ablation of FGFR2-IIIc isoform
resulted in a gain-of-function mutation, characterized by
neonatal growth retardation and death, coronal synostosis,
ocular proptosis, precocious sternal fusion, and abnormali-
ties in secondary branching in several organs that undergo
branching morphogenesis [38]. The discrepancies observed
between the two models could be explained by the fact
that the knockin mutation causes a splice switch, inducing
ectopic expression of the FGFR2-IIIb isoform. These results
highlight the diﬀerences that can arise from diﬀerent in
vivo approaches and underline the signiﬁcance of careful
experimental design.6 Journal of Nucleic Acids
3.2. Ret. Mouse models have been generated to investigate
the respective physiological functions of Ret9 and Ret51
(Figure 1), the two major isoforms of Ret, a receptor previ-
ously reported to play a critical role in kidney organogenesis
and the development of the enteric nervous system [39].
Partial cDNAs encoding the C-terminal intracellular part of
human Ret9 or Ret51 were inserted in frame into exon 11
of the mouse locus, immediately after the segment encoding
the transmembrane domain, thereby generating mice that
express either Ret9 or Ret51 isoforms. Ret9 mice, which
lack Ret51, were viable and appeared normal, demonstrating
that the expression of Ret9 alone is suﬃcient to support
normal embryogenesis and postnatal life. In contrast, Ret51
mice, which lack Ret9, displayed severe innervation defects
resulting in kidney hypodysplasia and a lack of enteric
ganglia from the colon [39]. As mentioned above, both Ret
isoforms diﬀer by the sequence context of the multidocking
phosphorylated Tyr-1062 site. The generation of knockin
mice in which Tyr-1062 of either Ret9 or Ret51 was mutated
to phenylalanine demonstrated that this residue plays a
critical role in speciﬁc Ret9 requirement in the develop-
ment of the kidneys and the enteric nervous system [40].
Interestingly, these ﬁndings provide direct in vivo evidence
that the distinct activities of Ret9 and Ret51 isoforms
result from the diﬀerential regulation of Tyr-1062-mediated
signaling through alternative splicing of C-terminal ﬂanking
sequences.
3.3. ErbB4. The case of ErbB4 appears more complex be-
cause of alternative splicing both in the extracellular jux-
tamembrane region and in the cytoplasmic C-terminal tail,
giving rise to four distinct isoforms with diﬀerential tissue-
speciﬁc expression (Figure 1). ErbB4, also known as HER4,
belongs to the ErbB/HER/EGFR family of tyrosine kinase
receptors. It binds to and is activated by neuregulins-2 and
-3, heparin-binding EGF-like growth factor and betacellulin
[41]. As mentioned above, the ligand-induced proteolysis of
ErbB4 JM-a isoforms releases soluble intracellular domains
of 80kDa called s80Cyt2 and s80Cyt1, which exhibit nuclear
cytoplasmic shuttling and diﬀer by the 16-amino acid CYT-
1 speciﬁc sequence absent from CYT-2 isoforms [18, 19].
Owing to the lack of speciﬁc knockout mouse models, the
respective contribution of the diﬀerent ErbB4 isoforms to
neuregulin-induced signaling remains poorly understood.
However, Muraoka-Cook et al. generated transgenic mice
to compare the eﬀect of induced expression of s80Cyt1
or s80Cyt2 on mammary epithelium in vivo [42]. These
mice express the GFP-tagged intracellular domain of either
ErbB4-Cyt1 or ErbB4-Cyt2 isoforms under the control of
a doxycycline-inducible reverse tetracycline transcriptional
activator- (rtTA-) dependent promoter. Induced expression
of either isoform in the mammary gland was obtained
by crossing with transgenic mice expressing rtTA under
the control of the mouse mammary tumor virus LTR.
Interestingly, the resulting phenotypes revealed that the
s80Cyt1 and s80Cyt2 isoforms exert markedly opposing
eﬀects on mammary epithelium growth and diﬀerentiation.
Expression of s80Cyt1 during puberty decreased prolif-
eration and caused precocious lactogenesis in the ductal
epithelium of virgin mice. In contrast, expression of s80Cyt2
causedepithelialhyperplasia,characterizedbyincreasedWnt
and nuclear β-catenin expression, and elevated expression of
c-myc and cyclin D1 in the mammary epithelium. Although
these models do not allow assigning speciﬁc physiological
functions to the four ErbB4 isoforms, they clearly indicate
that the single insertion of 16 amino acids in the C-terminal
part of the receptor via alternative splicing is suﬃcient to
confer ErbB4 isoforms opposite biological eﬀects.
3.4. VEGFR-1 and VEGFR-2. VEGFR-1 and VEGFR-2 arose
through gene duplication during evolution resulting in a
highly similar exon-intron structure. Consequently, both
genes are subjected to the same alternative splicing mech-
anism giving rise to the production of secreted soluble
extracellular domains, named sVEGFR-1 and sVEGFR-2
(Figure 1), that have retained their ligand-binding capacity
[32, 33]. Since their discovery, a putative ligand trap role
has been proposed for such splice variants, which was
further exploited for the development of VEGF-targeted
antitumortherapies[30].However,thedirectdemonstration
ofphysiologicalfunctionsforbothsVEGFR-1andsVEGFR-2
soluble isoforms has come from studies in mice.
The ﬁrst mouse model demonstrated that sVEGFR-1 can
act as a positive modulator of vascular sprout formation
and branching morphogenesis [43]. In the course of their
investigation on the eﬀects of a VEGFR-1−/− null mutation
on blood vessel formation, the authors noticed aberrant
morphogenesis of embryonic vessels. This phenotype was
rescued with a sVEGFR-1 transgene suggesting a model
whereby sVEGFR-1 isoform locally traps VEGF-A to estab-
lish or modify a gradient that regulates vascular sprouting
and endothelial cell migration. The role of sVEGFR-1 was
also investigated in cornea avascularity using three comple-
mentary strategies in the mouse [44]. Corneal avascularity is
requiredforopticalclarityandoptimalvision.Themolecular
mechanisms responsible for this absence of blood vessels in
the cornea have remained enigmatic for a long time, owing
to the presence of VEGF-A in the cornea and its proximity
to vascularized tissues. Using neutralizing antibodies, RNA
interference and Cre-lox-mediated gene disruption, Ambati
and colleagues have demonstrated that the presence of
sVEGFR-1 is necessary and suﬃcient to trap VEGF-A in the
cornea, thereby inhibiting angiogenesis [44]. Interestingly,
the mouse cornea also expresses sVEGFR-2, but not the full-
length VEGFR-2 receptor [33]. Loss of sVEGFR-2 expression
in the cornea obtained by tissue-speciﬁc targeted disruption
of the VEGFR-2 gene resulted in lymphatic invasion of
the normally alymphatic cornea at birth. These results
show that sVEGFR-2 act as an endogenous inhibitor of
lymphangiogenesis by trapping VEGF-C.
3.5. TrkB. The putative physiological role of the alterna-
tively spliced TrkB-T1 truncated receptor has been ini-
tially investigated in transgenic mice over expressing it
in postnatal cortical and hippocampal neurons [45, 46].
These animals have impaired long-term spatial memory, a
phenotype similar to that of BDNF knockout mice [47],Journal of Nucleic Acids 7
and show increased susceptibility to cortical injury after
focal cerebral ischemia. Therefore, these studies suggested
that TrkB-T1 could indeed act as a dominant negative
receptor inhibiting BDNF signaling, at least in some types
of brain functions. More recently, however, the functions
of TrkB-T1 were reassessed in a knockout mouse model
with a selective ablation of this isoform that did not aﬀect
the spatiotemporal expression of the full-length receptor
[48, 49]. Surprisingly, TrkB-T1-deﬁcient mice do not show
any overt phenotype, although they are more anxious than
their control littermates and display morphological changes
in the length and complexity of neurites of the basolateral
amygdala neurons. Moreover, although loss of TrkB-T1
does not aﬀect normal brain development or function, its
reduction can improve deﬁciencies associated with BDNF
haploinsuﬃciency, thereby clearly demonstrating that TrkB-
T1 can limit BDNF/TrkB signaling in a physiological
manner.
3.6. B-Raf. T h es t u d i e sd e s c r i b e da b o v eh a v ep r o v i d e d
various examples of the physiological relevance for alterna-
tive splicing of genes encoding membrane-bound tyrosine
kinase receptors otherwise implicated in human cancers.
In contrast, only one study has been conducted in vivo
to investigate such physiological functions of splice vari-
ants of a cytosolic oncogenic protein kinase, thus far. As
alreadymentioned,theB-raf geneencodesmultipleisoforms
displaying tissue-speciﬁc expression [50, 51]. The kinase
activity of the diﬀerent B-Raf isoforms is modulated by
the presence or absence of sequences encoded by exon 8b
and 9b, located in the hinge region upstream of the kinase
domain(Figure 1).Whileexon9bisconservedinvertebrates,
including ﬁsh, amphibians, avians, and mammals, exon 8b
appeared later during evolution since it is found only in
eutherians, but not in other mammals such as marsupialia
and monotremata [52]. To investigate the physiological
relevance of B-raf alternative splicing during development,
conditionalknockoutmiceforeitherexon8borexon9bwere
generated. In contrast with the complete B-raf knockout,
none of these exons were required for normal development,
since adult animals carrying a homozygous constitutive
mutation (B-rafΔ8b/Δ8b or B-rafΔ9b/Δ9 b )s u r v i v e du pt o
at least 18 months in the absence of detectable anomalies
[52]. However, behavioral analyses revealed that expression
of exon 9b-containing isoforms was required for B-Raf
function in hippocampal-dependent learning and memory.
In contrast, mice carrying a mutation of exon 8b were not
impaired in this function. It has been proposed that the
requirement for exon 9b-containing isoforms was due to
theirresistancetoPKA-mediatedinhibitoryphosphorylation
on Ser-365 and Ser-429 (Figure 1), allowing convergence
of PKA and ERK signaling on nuclear targets involved in
the process. Interestingly, this study also revealed that the
putative function of exon 8b-containing B-Raf isoforms,
which remains to be characterized, has probably evolved
duringevolutionsincealternativesplicingofexon8bappears
diﬀerentially regulated in primates, as compared with other
mammals [52].
4. AlternativeSplicingof Oncogenic
Kinases andCancer
As for most oncogenes and tumor suppressor genes, per-
turbations in alternative splicing can modify the expression
and activity of oncogenic kinases during tumor development
and maintenance. Such phenomenons sometime proceed
from the deregulation of an otherwise normal physiological
alternativesplicing,asillustratedbelowbyexamplesfromthe
FGFR, ErbB, and Trk families of tyrosine kinase receptors. In
other cases such as Abl or Aurora kinases, it is not clearly
established whether the alternative splicing mechanism
implicated in tumor progression also plays physiological
roles in the nonpathological functions of the kinase. Finally,
Jak2, Kit, Ron, and Met kinases provide typical examples of
aberrant splicing generating oncogenic splice variants that
are not usually observed in nonpathological conditions. We
will review here some of these, by focusing speciﬁcally on
oncogenic kinases whose splicing proﬁles are associated with
an established functional consequence in cancer.
4.1. FGFRs. The involvement of FGFR2 spliced isoforms in
developmental processes was described above. Interestingly,
alternative splicing of FGFR2 also appears to be implicated
in cancer. FGFR2 exon switching from the IIIb to the IIIc
isoform has been observed during epithelial cell tumor
progression, notably in breast cancer [53–55]. FGFR2 IIIc
expressionisassociatedwithalossofepithelialmarkersanda
gain of mesenchymal markers. Furthermore, the C-terminus
of FGFR2-IIIb also undergoes additional alternative splicing,
thereby modulating its oncogenic activity [54–56]. Thus,
breastcancerprogressionmayinvolvetwodistinctalternative
splicing events, ﬁrst involving the expression of FGFR2 IIIb
C2/C3 isoforms associated with progression from normal
breast epithelium to noninvasive breast cancer, and secondly
involving the conversion to the mesenchymal FGFR2 IIIc
isoform in invasive breast cancer cells [55].
Studies in cancer cells further revealed an even more
complicated regulation of the FGFR receptors family activity
by alternative splicing [57]. For example, FGFR1 exhibits
another RNA splicing event that results in skipping of the
exon encoding the Ig-like domain I [58]. The receptor
containing only two Ig-like domains (FGFR1-β) displays a
higher binding aﬃnity for FGF1 [59, 60] and, unlike the full-
length FRFR1-α isoform, caused cancer in a model of nude
mice xenograft [61]. An increase in the FGFR1-β levels has
beenassociatedwithtumorprogression,reducedrelapse-free
survival, and malignancy in astrocytomas, breast, pancreatic,
and bladder cancers [62–64]. However, little is known about
the biological and functional consequences of increased
expression of FGFR1-β in cancer cells.
4.2. ErbB2. The transmembrane HER2/ErbB2/Neu tyrosine
kinasereceptorbelongstotheepidermalgrowthfactorrecep-
tor (EGFR) family. Overexpression and gene ampliﬁcation
of ErbB2 are frequently observed in human malignancies,
in particular in 25–30% of primary human breast cancers
[65]. This correlates with enhanced tumor aggressiveness8 Journal of Nucleic Acids
and poor patient outcome. Several studies have reported
the expression of an ErbB2 alternatively spliced isoform in
normal mammary cells and in human breast carcinomas
[66]. The in-frame deletion of 16 amino acids in the
juxtamembrane domain due to exon 16 splicing induces the
formation of ΔErbB2 that displays a stronger transforming
activity than wildtype ErbB2. Structural analyses of the
ErbB2 extracellular domain have shown that electrostatic
repulsions may probably prevent homodimerization of this
receptor [67]. Splicing in ΔErbB2 is supposed to trigger
the kinase activity by promoting intermolecular disulﬁde
bonding and, in turn, homodimers capable of transforming
cells. Levels of the ErbB2 splice variant are only 5% of those
observedwiththewildtypereceptor,bothinprimarynormal
breast tissue and breast cancers. ErbB2 gene ampliﬁcation in
primary human breast cancer might increase the levels of
this oncogenic variant above a critical threshold, therefore
allowing it to contribute to breast cancer progression [68].
4.3. TrkB. As previously mentioned, studies using knockout
mice demonstrated that at physiological levels, TrkB-T1 acts
as a dominant negative receptor inhibiting BDNF signaling
inbrainneurons.However,invitrostudiessuggestthatTrkB-
T1 may also have signaling properties on its own [27–29].
In support of this, overexpression of TrkB-T1 but not a
TrkB-T1 COOH-terminal deletion mutant in nonmetastatic
pancreatic cancer cells was shown to induce liver metastasis
in an orthotopic xenograft mouse model of pancreatic
cancer by sequestering Rho GDP dissociation inhibitor and
promoting RhoA activation [69]. Accordingly, TrkB-T1 but
notfull-lengthTrkBisoverexpressedinpancreaticcancercell
lines and pancreatic tumor samples [69].
4.4. Aurora. Aurora kinases are a family of serine and threo-
nineproteinkinasesthatfunctionaskeyregulatorsofmitosis
by controlling the accurate and equal segregation of chro-
mosomes. Two members, Aurora-A and -B, are frequently
overexpressed in a wide variety of human cancers. Aberrant
expression of these kinases correlates with poor prognosis
and is implicated in oncogenic transformation mainly by
inducing chromosomal instability. The expression of dif-
ferent 5 UTR alternative splicing variants of Aurora-A was
ﬁrst reported in breast cancer cell lines and primary tumors
[70]. Lai et al. also described that the exon 2-containing
variant,whichcontributestoAurora-Aoverexpressionunder
EGF treatment, is dominantly expressed in colorectal cancer
tissues compared to normal human colon tissues [71]. The
recruitment of speciﬁc splicing variants of Aurora-A mRNA
in regulating Aurora-A protein expression indicates that
there could be a potential correlation between exon 2-
containing variant and colorectal cancer development. Two
Aurora-B alternative splicing variants were also identiﬁed
in liver cancer cells and tumor biopsies [72]. AURKB-Sv1
retained46bpofintron5andlost96bpofexon5,whileexon
6 is missing in AURKB-Sv2. The variant form was absent
in normal liver and was overexpressed in metastatic liver
cancer compared to hepatocellular carcinoma (HCC). This
aberrant expression was associated with the advanced stages
of HCC, and correlated with a poor outcome and a shorter
disease-freeperiod.ThissuggestedthatAURKB-Sv2couldbe
a marker of poor prognosis in hepatocarcinogenesis. Further
experiments are necessary to elucidate the structural and
functional properties of this alternative splicing in HCC. Of
note,theputativephysiologicalfunctionsofsplicevariantsof
Aurorakinaseshavenotbeenassessedinmousemodels,thus
far.
4.5. ABL. Myeloproliferative neoplasias (MPNs) are
hematopoietic stem cell disorders linked to uncontrolled
overproduction of mature and functional blood cells.
Chronic myeloid leukemia (CML), the most common
MPN, is characterized by a chromosomal translocation,
which leads to the production of the breakpoint cluster
region-abelson (BCR-ABL) fusion oncoprotein. BCR-ABL
contains a constitutively activated tyrosine kinase domain
that plays a role in malignant transformation and triggers
CML. Numerous BCR-ABL alternative spliced variants have
been reported [73–76]. For instance, the 35-bp insertion
of ABL intron 8 between exon 8 and exon 9 results in
a reading-frame shift and leads to the expression of a
truncated protein missing the last 14 residues of the kinase
domain and the following C-terminus residues. However,
ABL alternative splicing appears to be quite frequent in
the normal population and an increase in expression levels
and the frequency of these alternatively spliced BCR-ABL
associated with imatinib resistance in the chronic phase of
CML is still a matter of debate [77–79].
4.6. JAK2. Non-CML MPNs such as polycythemia vera
(PV), essential thrombocythemia (ET), or idiopathic mye-
loﬁbrosis (IMF) display recurrent anomalies in the JAK2
tyrosine kinase that plays a critical role in mediating
hematopoietic cytokine receptor signaling through the
JAK/STAT pathway [80]. The JAK2 V617F mutation in
exon 14 is the most common single-point mutation found
mainly implicated in chronic myeloproliferative disorders
(found in 35% to 95% of PV, ET, and IMF patients) [81,
82]. In vitro, the V617F substitution increases JAK2 kinase
activity, thus causing cytokine-independent growth of cell
lines and cultured bone marrow cells. From predicted JAK2
structure analysis, this mutation is believed to disrupt the
autoinhibitory interaction between the pseudokinase (JH2)
and kinase (JH1) domains thus allowing the activation
loop of JH1 to adopt a conformation in which it can
be phosphorylated by an adjacent JAK2V617F molecule.
Further investigations revealed that around 15% of patients
suﬀering from MPN also express a JAK2 exon 14 mRNA
splice transcript accounting for around 12% of total JAK2
transcripts [83, 84]. The deletion of exon 14 (88bp) leads
to the frame shift of seven amino acids followed by a
stop codon. The truncation of the JAK2 protein within the
pseudokinase domain thus results in deletion within the
JH2 domain and complete deletion of the kinase domain
(JH1). How this alternative short form of JAK2 is able to
activate the JAK2-STAT pathway remains unclear. Additional
functional studies are needed to demonstrate the role ofJournal of Nucleic Acids 9
the Δexon14 deletion in deregulating JAK2 activity and in
leukemogenesis.
4.7. Kit. The tyrosine kinase receptor c-Kit and its ligand
SCF (stem cell factor) play essential functions in a number
of cell types, including hematopoietic stem cells, mast cells,
melanocytes, and germ cells. Activating mutations of c-Kit
have been described in various human cancers, including
melanomas, testicular germinomas, acute myeloid leukemia,
and gastrointestinal stromal tumors (GIST). Many diﬀerent
alternative splicing sites in c-Kit were ﬁrst reported in
leukemia cells [85, 86]a n dt h e ni nG I S T[ 87, 88]. In GIST,
the loss of 27 nucleotides in exon 11 of c-Kit results in
polypeptides that remain in-frame but lack a nine amino
acids internal stretch that is crucial for autoinhibition of the
kinase. Structural studies of the mutated kinase revealed a
conformation consistent with constitutive activation [88].
4.8. Met. Signaling mediated by HGF/c-Met promotes a
widerangeofbiologicalactivitiesincludingcellgrowth,mor-
phogenic diﬀerentiation, motility, invasion, and angiogene-
sis. Dysregulation of this pathway has also been implicated
in the development and progression of various malignant
tumors. Identiﬁcation of activating germline mutations of c-
Met in hereditary papillary renal carcinomas provided the
ﬁrst evidence linking c-Met to human oncogenesis [89].
Afterward, many c-Met missense mutations were observed
in a wide variety of cancers. A majority of them are located
in the activation loop of the kinase domain. However,
somatic intronic mutations leading to an exon 14 in-frame
deletion originally observed in fetal mouse tissues, [90]
were also reported in approximately 3% of nonsmall cell
lung cancers [91–93] and in gastric cancer cell lines [94].
This missense mutation leads to an alternatively spliced
transcript that encodes a 47-amino acid deletion in the cyto-
plasmic juxtamembrane domain thus removing the Y1003
phosphorylation site necessary for Cbl E3-ligase binding.
Cellular analyses have shown that the Met deletion mutant
receptor displays decreased Cbl binding and ubiquitination,
prolonged protein stability, and sustained signaling on
ligandstimulationinagreementwithenhancedtransforming
properties [92, 95]. These results are consistent with an
important role of the c-Met alternatively spliced form in the
development and progression of human cancer.
4.9. Ron. Ron, the tyrosine kinase receptor for the
Macrophage-stimulating protein belongs to the MET proto-
oncogene family. Ron is a heterodimer (p185RON) derived
from the proteolytic cleavage of a single-chain common
precursor and is composed of a disulﬁde-linked 40kDa α-
chain and a 145kDa β-chain with intrinsic tyrosine kinase
activity. With the involvement in cell dissociation, motility,
and matrix invasion, Ron has been found to be essential in
embryonic development and in tumor invasive/malignant
phenotypes. Thus, elevated Ron expression has been found
in breast, colon, lung, bladder, and ovarian cancers. Impor-
tantly, Ron is expressed as a single sized mRNA resulting
fromconstitutivesplicinginnormaltissueswhereasincancer
cells, the altered expression of Ron is often accompanied
by the generation of Ron variants mainly through mRNA
splicing[96].Thissuggeststhataswitchfromtheconstitutive
to alternative splicing occurs in cancer cells.
A Ron isoform, named RonΔ165, was identiﬁed in
human gastric carcinoma cells and induces an invasive
phenotype in transfected cells [97]. RonΔ165 (165kDa) is
generated by the alternative splicing of exon 11 (147bp),
which leads to the in-frame deletion of a 49-amino acid
region in the β chain extracellular domain. By inducing a
drastic change in the three-dimensional structure through
aberrant intermolecular disulﬁde bridge formation, this
deletion enables the proteolytic cleavage thus enabling
cellular membrane anchorage of the receptor and rendering
the kinase constitutively active in the absence of its ligand
in the cytoplasm. Interestingly, abnormal accumulation of
RonΔ165 transcripts occurs in primary human colorectal
and breast carcinomas and correlates with the metastatic
phenotype [98, 99]. Ghigna et al. identiﬁed a silencer and
an enhancer of splicing within exon 12 that regulates the
level of inclusion of exon 11. An increase in RonΔ165 levels
is stimulated by binding of the SR protein SF2/ASF to one
of these regulatory elements. The authors speculate that
SF2/ASF could regulate malignant transformation of certain
epithelialtumorsbyinducingRonΔ165-dependentEMTand
that pharmacological treatment of aberrant splicing could
lead to new anticancer therapeutic approaches [100].
Two others spliced variants RonΔ155 and RonΔ160 were
also identiﬁed in human colon carcinoma cell lines and
primary tumors [98, 101]. RonΔ160 is derived from a
splicing mRNA transcript with an in-frame deletion of 109
amino acids coded by exons 5 and 6 and located in the Ron
β-chain extracellular sequences. The deletion does not aﬀect
the proteolytic processing, but induces structural changes
that could stabilize an active form of the membrane receptor
by disulﬁdebridges triggered oligomerization. Therefore,the
constitutive activation of RonΔ160 by autophosphorylation
increases its cell migration and invasion properties [102].
RonΔ155 presents a combined deletion of exons 5, 6,
and 11 in the extracellular domain of the β-chain thus
preventing its maturation into the α/β two-chain form. The
receptor is constitutively active and capable of inducing
tumor formation in vivo [98].
5. Conclusions and Perspectives
Splice variants have been described in many cancer-
associated proteins, and in particular in oncogenic kinases.
The biological activity of the majority of alternatively spliced
isoforms and their contribution to cancer biology is yet to be
elucidated. Nevertheless, the various examples described in
this review highlight the importance of alternative splicing
events in both physiological and pathological functions of
oncogenic kinases. In some cases, the alternative isoforms
are present in normal tissue but are aberrantly expressed in
the corresponding tumor. It is sometimes unclear whether
changing the proportion of a given set of splice variants may
contribute to cancer biology, independent of gene expression10 Journal of Nucleic Acids
levels. In other cases, pathogenic alternative splicing is
speciﬁc to the tumor and can be a consequence or a cancer-
causing event [103, 104] .H o w e v e r ,o n ec a n n o tr u l eo u t
the possibility that most of the so-called aberrant splicing
events described in tumors actually reﬂect the exploitation
of yet unidentiﬁed regulatory mechanisms normally used
at speciﬁc moments of the development or in response
to external stimuli. Thus, beside gene mutations, hijacking
alternative splicing mechanisms in kinase-encoding genes
represents another way for cancer cells to progress toward
malignancy.
It becomes evident that recently available large-scale
analyses will prove useful in identifying new mechanisms
of carcinogenesis involving alternative splicing of oncogenic
kinases. Although not focused on protein kinases, such
approacheshavebeenalreadyappliedfortheidentiﬁcationof
alternative splicing markers in various types of cancers [105–
110]. A recent screening that used small interfering RNA
for isoform-speciﬁc silencing, identiﬁed alternative splicing
in genes associated with cell survival as important targets
for breast and ovarian cancer [111]. For example, changing
the splicing pattern of the tyrosine kinase SYK altered cell
survival and mitotic progression whereas global knockdown
of the same gene had no eﬀect, suggesting a speciﬁc role for
SYK splice variants. With regard to physiological functions
of splice variants of oncogenic kinases in nonpathological
conditions, the examples reviewed here clearly highlight the
power of mouse genetics. Further development of knockout
models restricted to alternatively spliced exons will certainly
be beneﬁcial in identifying such functions.
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